<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=6786&amp;modal=1&amp;valnames=exclusion_criteria&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="504313" class="table-">
                
                <td>June 25, 2024, noon</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria">
            * having a history of covid-19 or a positive nucleic acid test for covid-19;
* having a history or a family history of allergy, convulsion, epilepsy, brain disease, or mental illness;
* being allergic to any component of vaccines, or having a history of severe allergic reaction to any vaccine;
* having immunodeficiency disorder, during treatment of malignant tumor, having immunodeficiency induced by immunosuppressants (oral steroid hormones) or hiv, or having a family member with close contact who suffers from congenital immune disorder;
* having injection of non-specific immunoglobulin within 1 month prior to enrollment;
* having acute febrile illness or communicable disease;
* having a history of confirmed thrombocytopenia or other coagulation disorders, which may cause contraindications for a subcutaneous injection;
* having severe chronic disease or acute exacerbation of chronic disease, or having uncontrolled hypertension or diabetes;
* having various infectious, pyogenic, or allergic skin diseases;
* women in pregnancy or lactation or participants who plan for a baby within 3 months after vaccination should delay the vaccination;
* having any condition that may affect trial assessment as determined by researchers.

exclusion criteria for the second dose:

* having any serious adverse event related to the first dose vaccination;
* after vaccination, having systemic adverse reaction or allergic reaction with a severity of grade 3 or higher as determined by researchers;
* having a newly emerging condition that meets the exclusion criteria for the first dose;
* having any condition that may affect trial assessment as determined by researchers.
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria validated">
            * having a history of covid-19 or a positive nucleic acid test for covid-19;
* having a history or a family history of allergy, convulsion, epilepsy, brain disease, or mental illness;
* being allergic to any component of vaccines, or having a history of severe allergic reaction to any vaccine;
* having immunodeficiency disorder, during treatment of malignant tumor, having immunodeficiency induced by immunosuppressants (oral steroid hormones) or hiv, or having a family member with close contact who suffers from congenital immune disorder;
* having injection of non-specific immunoglobulin within 1 month prior to enrollment;
* having acute febrile illness or communicable disease;
* having a history of confirmed thrombocytopenia or other coagulation disorders, which may cause contraindications for a subcutaneous injection;
* having severe chronic disease or acute exacerbation of chronic disease, or having uncontrolled hypertension or diabetes;
* having various infectious, pyogenic, or allergic skin diseases;
* women in pregnancy or lactation or participants who plan for a baby within 3 months after vaccination should delay the vaccination;
* having any condition that may affect trial assessment as determined by researchers.

exclusion criteria for the second dose:

* having any serious adverse event related to the first dose vaccination;
* after vaccination, having systemic adverse reaction or allergic reaction with a severity of grade 3 or higher as determined by researchers;
* having a newly emerging condition that meets the exclusion criteria for the first dose;
* having any condition that may affect trial assessment as determined by researchers.
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="144332" class="table-">
                
                <td>Oct. 16, 2021, 3 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria">
            -  having a history of covid-19 or a positive nucleic acid test for covid-19;

          -  having a history or a family history of allergy, convulsion, epilepsy, brain disease,
             or mental illness;

          -  being allergic to any component of vaccines, or having a history of severe allergic
             reaction to any vaccine;

          -  having immunodeficiency disorder, during treatment of malignant tumor, having
             immunodeficiency induced by immunosuppressants (oral steroid hormones) or hiv, or
             having a family member with close contact who suffers from congenital immune disorder;

          -  having injection of non-specific immunoglobulin within 1 month prior to enrollment;

          -  having acute febrile illness or communicable disease;

          -  having a history of confirmed thrombocytopenia or other coagulation disorders, which
             may cause contraindications for a subcutaneous injection;

          -  having severe chronic disease or acute exacerbation of chronic disease, or having
             uncontrolled hypertension or diabetes;

          -  having various infectious, pyogenic, or allergic skin diseases;

          -  women in pregnancy or lactation or participants who plan for a baby within 3 months
             after vaccination should delay the vaccination;

          -  having any condition that may affect trial assessment as determined by researchers.

        exclusion criteria for the second dose:

          -  having any serious adverse event related to the first dose vaccination;

          -  after vaccination, having systemic adverse reaction or allergic reaction with a
             severity of grade 3 or higher as determined by researchers;

          -  having a newly emerging condition that meets the exclusion criteria for the first
             dose;

          -  having any condition that may affect trial assessment as determined by researchers.
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria validated">
            -  having a history of covid-19 or a positive nucleic acid test for covid-19;

          -  having a history or a family history of allergy, convulsion, epilepsy, brain disease,
             or mental illness;

          -  being allergic to any component of vaccines, or having a history of severe allergic
             reaction to any vaccine;

          -  having immunodeficiency disorder, during treatment of malignant tumor, having
             immunodeficiency induced by immunosuppressants (oral steroid hormones) or hiv, or
             having a family member with close contact who suffers from congenital immune disorder;

          -  having injection of non-specific immunoglobulin within 1 month prior to enrollment;

          -  having acute febrile illness or communicable disease;

          -  having a history of confirmed thrombocytopenia or other coagulation disorders, which
             may cause contraindications for a subcutaneous injection;

          -  having severe chronic disease or acute exacerbation of chronic disease, or having
             uncontrolled hypertension or diabetes;

          -  having various infectious, pyogenic, or allergic skin diseases;

          -  women in pregnancy or lactation or participants who plan for a baby within 3 months
             after vaccination should delay the vaccination;

          -  having any condition that may affect trial assessment as determined by researchers.

        exclusion criteria for the second dose:

          -  having any serious adverse event related to the first dose vaccination;

          -  after vaccination, having systemic adverse reaction or allergic reaction with a
             severity of grade 3 or higher as determined by researchers;

          -  having a newly emerging condition that meets the exclusion criteria for the first
             dose;

          -  having any condition that may affect trial assessment as determined by researchers.
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	* having a history of covid-19 or a positive nucleic acid test for covid-19; * having a history or a family history of allergy, convulsion, epilepsy, brain disease, or mental illness; * being allergic to any component of vaccines, or having a history of severe allergic reaction to any vaccine; * having immunodeficiency disorder, during treatment of malignant tumor, having immunodeficiency induced by immunosuppressants (oral steroid hormones) or hiv, or having a family member with close contact who suffers from congenital immune disorder; * having injection of non-specific immunoglobulin within 1 month prior to enrollment; * having acute febrile illness or communicable disease; * having a history of confirmed thrombocytopenia or other coagulation disorders, which may cause contraindications for a subcutaneous injection; * having severe chronic disease or acute exacerbation of chronic disease, or having uncontrolled hypertension or diabetes; * having various infectious, pyogenic, or allergic skin diseases; * women in pregnancy or lactation or participants who plan for a baby within 3 months after vaccination should delay the vaccination; * having any condition that may affect trial assessment as determined by researchers. exclusion criteria for the second dose: * having any serious adverse event related to the first dose vaccination; * after vaccination, having systemic adverse reaction or allergic reaction with a severity of grade 3 or higher as determined by researchers; * having a newly emerging condition that meets the exclusion criteria for the first dose; * having any condition that may affect trial assessment as determined by researchers.	* having a history of covid-19 or a positive nucleic acid test for covid-19; * having a history or a family history of allergy, convulsion, epilepsy, brain disease, or mental illness; * being allergic to any component of vaccines, or having a history of severe allergic reaction to any vaccine; * having immunodeficiency disorder, during treatment of malignant tumor, having immunodeficiency induced by immunosuppressants (oral steroid hormones) or hiv, or having a family member with close contact who suffers from congenital immune disorder; * having injection of non-specific immunoglobulin within 1 month prior to enrollment; * having acute febrile illness or communicable disease; * having a history of confirmed thrombocytopenia or other coagulation disorders, which may cause contraindications for a subcutaneous injection; * having severe chronic disease or acute exacerbation of chronic disease, or having uncontrolled hypertension or diabetes; * having various infectious, pyogenic, or allergic skin diseases; * women in pregnancy or lactation or participants who plan for a baby within 3 months after vaccination should delay the vaccination; * having any condition that may affect trial assessment as determined by researchers. exclusion criteria for the second dose: * having any serious adverse event related to the first dose vaccination; * after vaccination, having systemic adverse reaction or allergic reaction with a severity of grade 3 or higher as determined by researchers; * having a newly emerging condition that meets the exclusion criteria for the first dose; * having any condition that may affect trial assessment as determined by researchers.
Oct. 16, 2021, 3 p.m.	usa	- having a history of covid-19 or a positive nucleic acid test for covid-19; - having a history or a family history of allergy, convulsion, epilepsy, brain disease, or mental illness; - being allergic to any component of vaccines, or having a history of severe allergic reaction to any vaccine; - having immunodeficiency disorder, during treatment of malignant tumor, having immunodeficiency induced by immunosuppressants (oral steroid hormones) or hiv, or having a family member with close contact who suffers from congenital immune disorder; - having injection of non-specific immunoglobulin within 1 month prior to enrollment; - having acute febrile illness or communicable disease; - having a history of confirmed thrombocytopenia or other coagulation disorders, which may cause contraindications for a subcutaneous injection; - having severe chronic disease or acute exacerbation of chronic disease, or having uncontrolled hypertension or diabetes; - having various infectious, pyogenic, or allergic skin diseases; - women in pregnancy or lactation or participants who plan for a baby within 3 months after vaccination should delay the vaccination; - having any condition that may affect trial assessment as determined by researchers. exclusion criteria for the second dose: - having any serious adverse event related to the first dose vaccination; - after vaccination, having systemic adverse reaction or allergic reaction with a severity of grade 3 or higher as determined by researchers; - having a newly emerging condition that meets the exclusion criteria for the first dose; - having any condition that may affect trial assessment as determined by researchers.	- having a history of covid-19 or a positive nucleic acid test for covid-19; - having a history or a family history of allergy, convulsion, epilepsy, brain disease, or mental illness; - being allergic to any component of vaccines, or having a history of severe allergic reaction to any vaccine; - having immunodeficiency disorder, during treatment of malignant tumor, having immunodeficiency induced by immunosuppressants (oral steroid hormones) or hiv, or having a family member with close contact who suffers from congenital immune disorder; - having injection of non-specific immunoglobulin within 1 month prior to enrollment; - having acute febrile illness or communicable disease; - having a history of confirmed thrombocytopenia or other coagulation disorders, which may cause contraindications for a subcutaneous injection; - having severe chronic disease or acute exacerbation of chronic disease, or having uncontrolled hypertension or diabetes; - having various infectious, pyogenic, or allergic skin diseases; - women in pregnancy or lactation or participants who plan for a baby within 3 months after vaccination should delay the vaccination; - having any condition that may affect trial assessment as determined by researchers. exclusion criteria for the second dose: - having any serious adverse event related to the first dose vaccination; - after vaccination, having systemic adverse reaction or allergic reaction with a severity of grade 3 or higher as determined by researchers; - having a newly emerging condition that meets the exclusion criteria for the first dose; - having any condition that may affect trial assessment as determined by researchers.